8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Mar 12, 2026·SEC
Xenon Pharmaceuticals Inc.(XENE)Earnings, Financials & Key Ratios
XENE•NASDAQ
$58.56
$4.69B mkt cap·Price updated May 6, 2026
AboutXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.Show more
- Revenue$8M
- EBITDA-$373M-34.8%
- Net Income-$346M-47.6%
- EPS (Diluted)-4.36-44.9%
- EBITDA Margin-4974.27%
- Operating Margin-4974.27%
- Net Margin-4612.13%
- ROE-51.76%-85.8%
- ROIC-55.31%-86.3%
- Debt/Equity0.01+14.3%
XENE Key Insights
Xenon Pharmaceuticals Inc. (XENE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 25.3% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XENE Price & Volume
Xenon Pharmaceuticals Inc. (XENE) stock price & volume — 10-year historical chart
Loading chart...
XENE Growth Metrics
Xenon Pharmaceuticals Inc. (XENE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.05%
5 Years-25.26%
3 Years-7.36%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-44.37%
Return on Capital
10 Years-36.47%
5 Years-31.05%
3 Years-37.87%
Last Year-55.11%
XENE Recent Earnings
Xenon Pharmaceuticals Inc. (XENE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 2/12 qtrs (100%)
Q1 2026Latest
Feb 26, 2026EPS
$1.31
Est $1.20
-9.2%
Revenue
—
Est $178,571
Q4 2025
Nov 3, 2025EPS
$1.15
Est $1.16
+0.9%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$1.07
Est $1.03
-3.9%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.83
Est $0.94
+11.7%
Revenue
$8M
Est $2M
+293.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.31vs $1.20-9.2% | —vs $178,571 |
| Q4 2025 | Nov 3, 2025 | $1.15vs $1.16+0.9% | — |
| Q3 2025 | Aug 11, 2025 | $1.07vs $1.03-3.9% | — |
| Q2 2025 | May 12, 2025 | $0.83vs $0.94+11.7% | $8Mvs $2M+293.4% |
Based on last 12 quarters of dataView full earnings history →
XENE Peer Comparison
Xenon Pharmaceuticals Inc. (XENE) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 OVID | 361.91M | 2.78 | -11.58 | 11.81% | -240.11% | -23.98% | 0.01 | |
 LGND | 4.57B | 232.55 | -1057.05 | 27.28% | 19.34% | 5.11% | 0.01 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% |
Compare XENE vs Peers
Xenon Pharmaceuticals Inc. (XENE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XENE Income Statement
Xenon Pharmaceuticals Inc. (XENE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 311K | 0 | 6.83M | 32.17M | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Revenue Growth % | -82.75% | -100% | - | 371.02% | -42.68% | -48.83% | -100% | - | - |
| Cost of Goods Sold | 25.57M | 6M | 0 | 0 | 0 | 0 | 167.51M | 2.56M | 0 |
| COGS % of Revenue | 8222.83% | - | - | - | - | - | - | - | - |
| Gross Profit | -25.26M▲ 0% | -6M▲ 76.2% | 6.83M▲ 213.8% | 32.17M▲ 371.0% | 18.44M▼ 42.7% | 9.43M▼ 48.8% | -167.51M▼ 1875.6% | -2.56M▲ 98.5% | 0▲ 100.0% |
| Gross Margin % | -8122.83% | - | 100% | 100% | 100% | 100% | - | - | - |
| Gross Profit Growth % | -3766.47% | 76.25% | 213.82% | 371.02% | -42.68% | -48.83% | -1875.62% | 98.47% | 100% |
| Operating Expenses | 32.89M | 32.02M | 49.65M | 63.47M | 97.43M | 138.58M | 46.54M | 276.74M | 380.57M |
| OpEx % of Revenue | 10574.28% | - | 727.02% | 197.31% | 528.45% | 1468.91% | - | - | 5074.27% |
| Selling, General & Admin | 7.31M | 8.38M | 10.8M | 12.94M | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| SG&A % of Revenue | 2351.45% | - | 158.19% | 40.24% | 119.15% | 347.78% | - | - | 1061.76% |
| Research & Development | 25.57M | 23.63M | 38.84M | 50.52M | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| R&D % of Revenue | 8222.83% | - | 568.82% | 157.07% | 409.3% | 1121.13% | - | - | 4012.51% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -167.51M | -2.56M | 0 |
| Operating Income | -32.58M▲ 0% | -38.02M▼ 16.7% | -42.82M▼ 12.6% | -31.3M▲ 26.9% | -78.99M▼ 152.4% | -129.14M▼ 63.5% | -214.05M▼ 65.7% | -279.3M▼ 30.5% | -373.07M▼ 33.6% |
| Operating Margin % | -10474.28% | - | -627.02% | -97.31% | -428.45% | -1368.91% | - | - | -4974.27% |
| Operating Income Growth % | -31.26% | -16.7% | -12.63% | 26.9% | -152.37% | -63.49% | -65.75% | -30.48% | -33.57% |
| EBITDA | -31.93M | -37.43M | -42.39M | -30.66M | -78.09M | -127.74M | -210.51M | -276.74M | -373.07M |
| EBITDA Margin % | -10265.59% | - | -620.74% | -95.31% | -423.53% | -1354.02% | - | - | -4974.27% |
| EBITDA Growth % | -33.29% | -17.24% | -13.25% | 27.68% | -154.71% | -63.58% | -64.8% | -31.46% | -34.81% |
| D&A (Non-Cash Add-back) | 649K | 586K | 429K | 644K | 906K | 1.41M | 3.54M | 2.56M | 0 |
| EBIT | -30.7M | -33.13M | -40.18M | -28.61M | -78.99M | -129.14M | -214.05M | -238.42M | 0 |
| Net Interest Income | 477K | -178K | 919K | 1.79M | 466K | 8.71M | 27.62M | 41.94M | 0 |
| Interest Income | 477K | 1.22M | 2.35M | 2.28M | 466K | 8.71M | 27.62M | 41.94M | 0 |
| Interest Expense | 0 | 1.39M | 1.43M | 484K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.87M | 6.4M | 1.2M | 2.21M | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Pretax Income | -30.7M▲ 0% | -34.5M▼ 12.4% | -41.62M▼ 20.6% | -29.09M▲ 30.1% | -78.89M▼ 171.1% | -125.25M▼ 58.8% | -182.69M▼ 45.9% | -238.42M▼ 30.5% | -344.89M▼ 44.7% |
| Pretax Margin % | -9872.67% | - | -609.43% | -90.45% | -427.88% | -1327.7% | - | - | -4598.59% |
| Income Tax | 0 | 4.91M | -23K | -257K | -6K | 118K | -292K | -4.09M | -1.02M |
| Effective Tax Rate % | 0% | -14.24% | 0.06% | 0.88% | 0.01% | -0.09% | 0.16% | 1.72% | 0.29% |
| Net Income | -30.7M▲ 0% | -34.5M▼ 12.4% | -41.59M▼ 20.6% | -28.84M▲ 30.7% | -78.88M▼ 173.5% | -125.37M▼ 58.9% | -182.39M▼ 45.5% | -234.33M▼ 28.5% | -345.91M▼ 47.6% |
| Net Margin % | -9872.67% | - | -609.09% | -89.65% | -427.85% | -1328.95% | - | - | -4612.13% |
| Net Income Growth % | -33.51% | -12.35% | -20.58% | 30.67% | -173.54% | -58.94% | -45.48% | -28.48% | -47.62% |
| Net Income (Continuing) | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M | -345.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.71▲ 0% | -1.78▼ 4.1% | -1.54▲ 13.5% | -0.83▲ 46.1% | -1.77▼ 113.3% | -2.06▼ 16.4% | -2.73▼ 32.5% | -3.01▼ 10.3% | -4.36▼ 44.9% |
| EPS Growth % | -15.54% | -4.09% | 13.48% | 46.1% | -113.25% | -16.38% | -32.52% | -10.26% | -44.85% |
| EPS (Basic) | -1.71 | -1.78 | -1.54 | -0.83 | -1.77 | -2.06 | -2.73 | -3.01 | -4.36 |
| Diluted Shares Outstanding | 18M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Basic Shares Outstanding | 17.99M | 19.43M | 25.94M | 34.54M | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
XENE Balance Sheet
Xenon Pharmaceuticals Inc. (XENE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 44.82M | 121.44M | 144.87M | 181.78M | 559.02M | 600.3M | 644.96M | 635.26M | 548.89M |
| Cash & Short-Term Investments | 43.67M | 119.31M | 141.36M | 177M | 551.77M | 592.09M | 638.08M | 626.9M | 548.89M |
| Cash Only | 20.49M | 67.75M | 24.75M | 45.01M | 175.69M | 57.24M | 148.64M | 142.71M | 199.16M |
| Short-Term Investments | 23.18M | 51.55M | 116.6M | 131.99M | 376.09M | 534.85M | 489.44M | 484.19M | 548.89M |
| Accounts Receivable | 438K | 151K | 813K | 1.82M | 2.77M | 986K | 874K | 1.47M | 1.37M |
| Days Sales Outstanding | 514.05 | - | 43.45 | 20.67 | 54.74 | 38.15 | - | - | 66.72 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 7.22M | 6.01M | 6.89M | -1.37M |
| Total Non-Current Assets | 1.3M | 991K | 2.83M | 7.4M | 12.99M | 153.85M | 319.84M | 162.88M | 84.28M |
| Property, Plant & Equipment | 1.07M | 991K | 2.59M | 6.88M | 12.52M | 16.91M | 18.85M | 18.22M | 0 |
| Fixed Asset Turnover | 0.29x | - | 2.63x | 4.68x | 1.47x | 0.56x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 128.68M | 292.79M | 127.5M | 0 |
| Other Non-Current Assets | 230K | -105K | 0 | 0 | 0 | 7.75M | 7.4M | 7.5M | 84.28M |
| Total Assets | 46.12M▲ 0% | 122.43M▲ 165.4% | 147.7M▲ 20.6% | 189.19M▲ 28.1% | 572.01M▲ 202.4% | 754.15M▲ 31.8% | 964.8M▲ 27.9% | 798.14M▼ 17.3% | 633.16M▼ 20.7% |
| Asset Turnover | 0.01x | - | 0.05x | 0.17x | 0.03x | 0.01x | - | - | 0.01x |
| Asset Growth % | -31.66% | 165.45% | 20.64% | 28.09% | 202.35% | 31.84% | 27.93% | -17.27% | -20.67% |
| Total Current Liabilities | 4.08M | 4.12M | 43.38M | 14.78M | 14.32M | 22.7M | 27.27M | 35.59M | 41.79M |
| Accounts Payable | 1.25M | 665K | 2.47M | 3.04M | 3.82M | 8.49M | 8.6M | 5.07M | 0 |
| Days Payables Outstanding | 17.88 | 40.45 | - | - | - | - | 18.73 | 722.87 | - |
| Short-Term Debt | 700K | 0 | 4.65M | 0 | 0 | 0 | 0 | 0 | 1.53M |
| Deferred Revenue (Current) | 0 | -15.01M | 29.74M | 3.64M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 44K | 1.73M | 3.45M | 2.86M | 5.94M | 5.82M | 347K | 9.93M | 40.26M |
| Current Ratio | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x | 13.13x |
| Quick Ratio | 10.98x | 29.48x | 3.34x | 12.30x | 39.03x | 26.44x | 23.65x | 17.85x | 13.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.1M | 15.01M | 12.34M | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M | 9.61M |
| Long-Term Debt | 6.1M | 15.01M | 10.89M | 0 | 0 | 0 | 0 | 0 | 6.41M |
| Capital Lease Obligations | 0 | 0 | 743K | 3.05M | 7.65M | 9.95M | 9.6M | 7.65M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.2M |
| Total Liabilities | 10.19M | 19.13M | 55.72M | 17.83M | 21.97M | 32.65M | 36.88M | 43.24M | 51.4M |
| Total Debt | 6.8M | 15.01M | 16.45M | 3.31M | 8.26M | 10.44M | 10.9M | 9.02M | 7.94M |
| Net Debt | -13.68M | -52.74M | -8.3M | -41.69M | -167.43M | -46.81M | -137.74M | -133.7M | -191.22M |
| Debt / Equity | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -27.27x | -29.86x | -64.67x | - | - | - | - | - |
| Total Equity | 35.93M▲ 0% | 103.3M▲ 187.5% | 91.98M▼ 11.0% | 171.35M▲ 86.3% | 550.03M▲ 221.0% | 721.5M▲ 31.2% | 927.92M▲ 28.6% | 754.9M▼ 18.6% | 581.76M▼ 22.9% |
| Equity Growth % | -43.77% | 187.46% | -10.96% | 86.3% | 220.99% | 31.17% | 28.61% | -18.65% | -22.94% |
| Book Value per Share | 2.00 | 5.32 | 3.55 | 4.96 | 12.61 | 11.92 | 13.87 | 9.69 | 7.34 |
| Total Shareholders' Equity | 35.93M | 103.3M | 91.98M | 171.35M | 550.03M | 721.5M | 927.92M | 754.9M | 633.16M |
| Common Stock | 173.84M | 265.92M | 294.24M | 397.75M | 783.17M | 1.07B | 1.44B | 1.46B | 1.6B |
| Retained Earnings | -173.39M | -207.88M | -249.66M | -278.49M | -357.37M | -482.75M | -665.14M | -899.47M | -1.25B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -990K | -990K | -990K | -990K | -990K | -3M | -77K | -1.61M | 335K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XENE Cash Flow Statement
Xenon Pharmaceuticals Inc. (XENE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.73M | -34.72M | -4.63M | -48.12M | -69.5M | -98.43M | -145.33M | -181.39M | -279.12M |
| Operating CF Margin % | -9236.66% | - | -67.83% | -149.61% | -376.97% | -1043.35% | - | - | -3721.57% |
| Operating CF Growth % | -46.81% | -20.88% | 86.66% | -938.95% | -44.42% | -41.62% | -47.64% | -24.81% | -53.88% |
| Net Income | -30.7M | -34.5M | -41.59M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M | -345.91M |
| Depreciation & Amortization | 649K | 586K | 429K | 644K | 906K | 1.62M | 3.54M | 2.56M | 2.54M |
| Stock-Based Compensation | 2.24M | 2.63M | 2.92M | 5.68M | 10.02M | 20.38M | 32.37M | 50.72M | 53.71M |
| Deferred Taxes | -1.47M | 646K | -133K | -285K | 58K | -44K | -292K | -8.86M | -3.2M |
| Other Non-Cash Items | 11K | -4.11M | 223K | 766K | 1.05M | 5.66M | -4.19M | 2.81M | 13.74M |
| Working Capital Changes | 556K | 30K | 33.52M | -26.09M | -2.65M | -676K | 5.63M | 5.71M | 0 |
| Change in Receivables | -232K | 175K | -653K | -1.03M | -459K | 1.76M | 130K | -614K | 0 |
| Change in Inventory | 613K | -783K | -4.54M | -2.02M | -2.97M | 0 | 0 | 0 | 0 |
| Change in Payables | -3K | 783K | 4.54M | 2.02M | 2.97M | 8.06M | 3.93M | 8.53M | 5.51M |
| Cash from Investing | 24.29M | -28.99M | -66.29M | -16.82M | -246.77M | -296M | -117.17M | 165M | 218M |
| Capital Expenditures | -315K | -507K | -1.24M | -2.64M | -2.05M | -2.89M | -5.62M | -3.08M | -799K |
| CapEx % of Revenue | 101.29% | - | 18.16% | 8.2% | 11.12% | 30.68% | - | - | 10.65% |
| Acquisitions | -52.62M | -48.52M | -75.44M | -214.71M | -144.75M | 296M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 52.62M | 48.52M | 75.44M | 214.71M | 144.75M | -296M | 0 | 0 | 574.45M |
| Cash from Financing | 7.07M | 111.59M | 27.52M | 85.8M | 447.54M | 278.47M | 353.52M | 12.13M | 117.11M |
| Debt Issued (Net) | 6.89M | 8.45M | 0 | -16.74M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 177K | 288K | 122K | 82K | 260K | 705K | 35K | 47K | 117.11M |
| Net Change in Cash | 3.39M▲ 0% | 47.27M▲ 1293.9% | -43M▼ 191.0% | 20.25M▲ 147.1% | 130.68M▲ 545.2% | -118.45M▼ 190.6% | 91.4M▲ 177.2% | -5.93M▼ 106.5% | 56.45M▲ 1051.8% |
| Free Cash Flow | -29.04M▲ 0% | -35.23M▼ 21.3% | -5.87M▲ 83.3% | -50.76M▼ 764.5% | -71.55M▼ 41.0% | -101.32M▼ 41.6% | -150.94M▼ 49.0% | -184.46M▼ 22.2% | -279.92M▼ 51.7% |
| FCF Margin % | -9337.94% | - | -85.99% | -157.81% | -388.09% | -1074.03% | - | - | -3732.23% |
| FCF Growth % | -46.33% | -21.31% | 83.33% | -764.46% | -40.96% | -41.61% | -48.97% | -22.21% | -51.75% |
| FCF per Share | -1.61 | -1.81 | -0.23 | -1.47 | -1.64 | -1.67 | -2.26 | -2.37 | -3.53 |
| FCF Conversion (FCF/Net Income) | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XENE Key Ratios
Xenon Pharmaceuticals Inc. (XENE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -36.81% | -61.51% | -49.55% | -42.6% | -21.9% | -21.87% | -19.72% | -22.12% | -27.85% | -51.76% |
| Return on Invested Capital (ROIC) | -75.68% | -70.76% | -78.32% | -47.85% | -22.01% | -23.13% | -18.32% | -21.92% | -29.68% | -55.31% |
| Gross Margin | 38.21% | -8122.83% | - | 100% | 100% | 100% | 100% | - | - | - |
| Net Margin | -1275.49% | -9872.67% | - | -609.09% | -89.65% | -427.85% | -1328.95% | - | - | -4612.13% |
| Debt / Equity | - | 0.19x | 0.15x | 0.18x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | - | - | -27.27x | -29.86x | -64.67x | - | - | - | - | - |
| FCF Conversion | 0.85x | 0.94x | 1.01x | 0.11x | 1.67x | 0.88x | 0.79x | 0.80x | 0.77x | 0.81x |
| Revenue Growth | -88.43% | -82.75% | -100% | - | 371.02% | -42.68% | -48.83% | -100% | - | - |
XENE SEC Filings & Documents
Xenon Pharmaceuticals Inc. (XENE) SEC filings — annual & quarterly reports (10-K, 10-Q)
XENE Frequently Asked Questions
Xenon Pharmaceuticals Inc. (XENE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue for fiscal year 2025. This represents a 48% decrease from $14.3M in 2012.
Xenon Pharmaceuticals Inc. (XENE) grew revenue by 0.0% over the past year. Growth has been modest.
Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $345.9M for fiscal year 2025.
Dividend & Returns
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $279.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More XENE
Xenon Pharmaceuticals Inc. (XENE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates